MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma

SIMPLE SUMMARY: Glioblastoma, the brain tumour with highest prevalence and lethality, exhibits a characteristic glycolytic phenotype with increased lactate production. Recently, we reported a MCT1 overexpression in GBMs tumours, being associated to tumour growth and aggressiveness. Thus, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Miranda-Gonçalves, Vera, Gonçalves, Céline S., Granja, Sara, Vieira de Castro, Joana, Reis, Rui M., Costa, Bruno M., Baltazar, Fátima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306807/
https://www.ncbi.nlm.nih.gov/pubmed/34298681
http://dx.doi.org/10.3390/cancers13143468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306807/
https://www.ncbi.nlm.nih.gov/pubmed/34298681
http://dx.doi.org/10.3390/cancers13143468

Ejemplares similares